These data indicate that endogenous CD8+ TRLs are critical in restricting ischemic brain injury from early stages (Supplemental Figure 2, B and C) to at least 2 weeks (Supplemental Figure 2D) after stroke. The gene discussed is CD8A; the disease is Stroke.